Methods and Compositions Comprising MHC Class I Peptides

JP2024517630A5Pending Publication Date: 2025-08-19BOARD OF RGT THE UNIV OF TEXAS SYST
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023563942
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-04-19
Filing Date
2022-04-18
Publication Date
2025-08-19

AI Technical Summary

Technical Problem

Adoptive T-cell therapy for cancer treatment, such as melanoma, faces limitations including toxicity and a lack of effective immunogenic targets for pancreatic, ovarian, gastric, lung, cervical, breast, and head and neck cancers, necessitating the identification of novel epitopes and target antigens.

Method used

Development of isolated peptides with at least 70% sequence identity to IYNGKLFDL (SEQ ID NO:1) or SSSQESVPK (SEQ ID NO:2), molecular complexes with MHC polypeptides, and methods to produce cancer-specific immune effector cells using these peptides, including engineering T cells with specific T cell receptors (TCRs) and administering them to patients.

Benefits of technology

Enhances targeted cancer treatment by stimulating a specific immune response, reducing toxicity, and improving therapeutic efficacy against difficult-to-treat malignancies by utilizing peptide-specific engineered T cells and TCRs.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000000_0001_ABST
    Figure 00000000_0001_ABST
  • Figure 00000000_0000_ABST
    Figure 00000000_0000_ABST
Patent Text Reader

Abstract

The present disclosure fulfills a need in the art by providing methods and compositions for treating and vaccinating individuals against cancer. Accordingly, aspects of the present disclosure relate to isolated peptides comprising at least 70% sequence identity to a peptide of SEQ ID NO:1 or 2. In some embodiments, the peptide comprises at least 6 consecutive amino acids for a peptide of SEQ ID NO:1 or 2. Further aspects relate to pharmaceutical compositions comprising the isolated peptides, nucleic acids encoding the peptides, and expression vectors and host cells comprising the nucleic acids of the present disclosure. Also provided are in vitro isolated dendritic cells comprising the peptides, nucleic acids, or expression vectors of the present disclosure. TIFF2024517630000012.tif55170
Need to check novelty before this filing date? Find Prior Art